Physician profile
Sabaa Joad
NPI 1629314372
$2,318.07
in general payments reported to CMS, 2019-2025
25 companies · $228 in 2025
The $228 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $45.14 · 2022: $20.53 · 2023: $1,015 · 2024: $1,009 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,137 · Gift: $59.40 · Education: $55.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,137.03 |
| Gift | $59.40 |
| Education | $55.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $300.81 | 2023-2024 | Mounjaro, Jardiance, Trulicity |
| Xeris Pharmaceuticals, INC. | $270.84 | 2023-2024 | Gvoke Hypopen, Recorlev |
| Ascensia Diabetes Care US INC. | $254.16 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $211.95 | 2024-2025 | |
| Amgen INC. | $181.11 | 2023-2025 | Prolia, Evenity |
| Abbott Laboratories | $128.52 | 2023-2025 | Freestyle Libre 3 |
| Insulet Corporation | $122.64 | 2023-2024 | Omnipod |
| Mannkind Corporation | $120.59 | 2023-2025 | Afrezza |
| Ascendis Pharma Endocrinology INC | $101.94 | 2023-2024 | |
| Corcept Therapeutics | $89.01 | 2025 | Korlym |
| Novo Nordisk INC | $86.77 | 2023 | Sogroya, Wegovy, Norditropin |
| Abbvie INC. | $73.06 | 2023-2024 | |
| Eton Pharmaceuticals, INC. | $65.62 | 2023 | Alkindi |
| Janssen Pharmaceuticals, INC | $45.14 | 2020 | |
| Dexcom, INC. | $39.79 | 2023 | Dexcom G6 Transmitter |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $36.88 | 2023 | Triptodur |
| Pfizer INC. | $30.80 | 2023 | |
| Kyowa Kirin, INC. | $27.62 | 2023 | Crysvita |
| Rhythm Pharmaceuticals, INC. | $25.84 | 2023 | Imcivree |
| Amryt Pharma Holdings LTD | $20.53 | 2022 | |
| Chiesi USA, INC. | $19.53 | 2024 | Mycapssa |
| Amphastar Pharmaceuticals, INC. | $18.19 | 2023 | Baqsimi |
| Sequel Med Tech, LLC | $17.07 | 2025 | Twiist |
| Tandem Diabetes Care, INC. | $16.88 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Tolmar, INC. | $12.78 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sabaa Joad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.